semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Parkinson Disease Clinical diagnosis of Parkinson's disease according to the UK Brain Bank criteria Subjects had clinically moderate to advanced severity of disease (Hoehn and Yahr stage 2 Subjects whose medical treatment had been on stable dosage of dopaminomimetics for at least 4 weeks before the study Subjects ability to walk with or without assistive device  Subjects had cardiovascular, inflammatory or musculoskeletal problems that could prevent them to participate in an exercise program Subjects whose mini mental status examination score was less than 26
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Parkinson's Disease Men or women aged 40 and older with the diagnosis of idiopathic PD per UK Brain Bank Hoehn-Yahr Stage I-III, on stable dopaminergic treatment regimen for equal or greater than 4 weeks prior to baseline Aerobic Fitness: VO2max below "very good" fitness levels for their age and gender at baseline cyle ergometry. To subjects who have room to improve their aerobic fitness, the investigators will enroll only those subjects whose VO2max is below "very good" fitness level (about 90% of the population) using age and gender based VO2max norms based review of 62 studies where VO2max was measured directly in healthy adult subjects in the USA, Canada and 7 European countries (Reference: Shvartz, E and Reibold, RC. Aerobic fitness norms for males and females aged 6 to 75 years: a review. Aviat Space Environ Med. 1990; 61:3-11) Cognitive function: No dementia per Movement Disorder Society Level I (Reference: Dubois, B, Burn, D, Goetz, C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007; 22:2314-2324) Current active drivers with a valid driver's license Veteran or non-veteran  Subjects unwilling or unable to give informed consent Secondary parkinsonism (e.g., drug induced) Parkinson-plus syndromes History of brain surgery for PD such as deep brain stimulation Corrected visual acuity less than 20/50 (due to effect on driving) Contraindications to exercise per ACSM for Exercise Testing and Training (Reference: American College of Sports Medicine. Cardiorespiratory Exercise Prescription. In: Ehrman JK, ed. ACSM's Guidelines for Exercise Testing and Prescription.6th ed. Baltimore: Lippincott Williams & Wilkins, 2010:448-462) No confounding acute or unstable medical, psychiatric, orthopedic condition. Subjects who have hypertension, diabetes mellitus, depression, or other common age related illness will be included if their disease under control with stable treatment regimen for at least 30 days Clinically significant TBI or PTSD Presence of other known medical or psychiatric comorbidity that in the investigator's opinion would compromise participation in the study Presence of dementia per Movement Disorder Society Level I
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Portal Hypertension Hepatic Encephalopathy The patient's gender is not limited, ≥ 18 years old and ≤ 75 years old; 2. Clinically diagnosed post-hepatitis B cirrhosis; 3. History of esophageal varices venous rupture confirmed by endoscopy, re-bleeding after standard treatment; 4. Liver function Child A or B; 5. Imaging (CT or MRI) suggests that the left/right first branch of the intrahepatic portal can construct a shunt; 6. Platelet count ≥ 50 × 109 / L; 7. Prothrombin time (PT) does not exceed the upper limit of the normal control for 3 seconds; 8. Serum creatinine concentration ≤115umol/L; 9. Patients and their families agree to join the clinical trial and sign an informed consent form  Imaging confirms portal vein thrombosis; 2. Patients who have undergone previous surgical treatment of portal hypertension (including splenectomy, surgical disconnection or shunt); 3. Combine any malignant tumor; 4. History of previous hepatic encephalopathy; 5. Consolidation of intractable ascites; 6. Pulmonary artery pressure > 40 mmHg, left ventricular ejection fraction < 50%, congestive heart failure or severe valvular insufficiency; 7. Others: persistent active bleeding, vital signs can not be maintained, blood ammonia ≥ 100, total bilirubin > 51umol / L failed to improve after symptomatic treatment; combined active infection, especially biliary system inflammation; female patients are pregnant Or lactation; severe contrast allergy
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease A diagnosis of idiopathic PD Sufficient knowledge of the Dutch language to fill out questionnaires Age 18 years or older at the time of diagnosis All disease stages, regardless of disease severity or disease duration Not having received care from a PDNS in the past two years A score of ≥ 18 on the Mini-Mental State Examination (MMSE13) and ≥ 12 on the Frontal Assessment Battery (FAB14)  A type of atypical parkinsonism caused by medication (e.g. neuroleptics), a metabolic disorder (e.g. Wilson's disease), encephalitis or a neurodegenerative disorder (e.g. multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome) Residing in a nursing home or another type of residential care facility (because the PDNS is not operational there) Any other medical or psychiatric disorder that, in the opinion of the researcher, may compromise participation in the study
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson's Disease PD group： Patients who meet the 2016 China Parkinson's diagnostic and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic Newly diagnosed primary PD patients, diagnosed within 3-6 months Informed consent to the study Age > 18 older Non-PD group Age, gender-matched PD group Non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history Informed consent to the study Age > 18 older  Severe craniocerebral trauma patients Disturbance of consciousness Severe organic diseases, cerebral hemorrhage, cerebral thrombosis, severe coronary heart disease and lung disease, severe liver and kidney dysfunction, severe diabetes, severe hearing And visual impairment History of severe brain tumors, encephalitis or brain surgery
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 21.0-85.0,  Parkinson Disease Physician-diagnosed Parkinson's disease aged 21-85 years Hoehn & Yahr stage <3 Currently living in the same household with a healthy spouse/partner who meets study and is willing to participate Willing and able to complete informed consent in English Willing to complete daily and weekly questionnaires and 6 dietary recalls over approximately 7 weeks Willing to avoid beer, wine, and cocktails on the day before and the day of the sugar probe tests Willing to provide urine and stool samples during the study collection periods Willing and able to fast (no food or drink, except water or tea) for a prolonged period of time during study urine collections Willing to maintain usual diet through the pre-baseline period Willing to make dietary changes to follow a Mediterranean dietary pattern during the intervention period  Does not meet above Atypical or secondary Parkinsonism History of deep brain stimulation Daily use of NSAIDs in the last 3 months or incidental use in the last 2 weeks prior to screening Daily use of anticholinergics or prokinetic agents Use of enemas or suppositories to alleviate constipation Use of another investigational product within 3 months of the screening visit Antibiotic use within 2 months from the day of stool collection Good adherence to the Mediterranean diet during the pre-baseline period (score >6) based on the 14-item Mediterranean Diet Assessment Tool Physician-diagnosed gastrointestinal disease or condition (such as ulcerative colitis, Crohn's disease, gastroparesis, cancer, peptic ulcer disease, Celiac disease, short bowel disease, ileostomy, colostomy) other than gastroesophageal reflux or diverticular disease
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Parkinson Disease Subjects over 60 years of age with a clinical diagnosis of Parkinson's disease Stages of the disease 2-3 of Hoehn and Yahr Not exposed to tobacco during any stage of their life No history of lung diseases No laboratory abnormalities No history of adverse reactions to nicotine Able to use nicotine nasal spray Residents of Mexico City able to attend for evaluations Under current treatment with levodopa at a stable dose Not currently receiving a monoamine oxidase inhibitor treatment  Unable to complete follow-up protocol Drug adverse reaction Death
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 21.0-95.0,  Parkinson Disease age 21 years or older PD diagnosed by a movement disorder specialist for 3 months or longer prior to recruitment PD medication regimen is stable over the last 3 months with no changes Hoehn & Yahr stage 2 (N = 13) and H&Y stage 3 (N=13) able to walk independently or with a simple assistive device (e.g., cane, walker) observed by the research team to have PD related gait disturbance such as FOG, shortened or irregular stride lengths, irregular step cadence, slowed speed while on their regular treatment regimen  diagnosed with a known Parkinson plus syndrome were previously exposed to vibration treatment for gait and balance presence of dementia (Montreal Cognitive Assessment < 21) additional disorders (not related to PD)impairing gait, stance, balance or coordination (e.g. stroke, leg amputations, or multiple sclerosis) history of implantable cardiac device or any other implanted electronic device except a deep brain stimulator (DBS) use of braces/orthotics that assist with walking are currently in physical therapy (PT) treatment for balance or gait peripheral neuropathy by exam any condition that, in the opinion of the PIs, would compromise participant safety, data integrity, or data interpretation Children under the age of 18
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Parkinson Disease Subjects aged > 50 years, diagnosed as suffering from PD and under follow up of the Movement Disorders Clinic in Soroka University Medical Center Subjects complaining of constipation  Subjects who did not perform a screening colonoscopy for colon cancer Subjects who are clinically undertreated according to last Movement Disorders specialist's impression at the clinic visit  Subjects who do not complain of constipation or seem clinically stable properly treated pharmacologically Subjects who already underwent a screening colonoscopy for colon cancer Subjects who suffer from a cognitive decline and could not give their consent, or patients who refuse to undergo a colonoscopy
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Syncope Over 18 years Diagnosis of neurally mediated syncope with a tilting table test (Tilt test) that demonstrates a mixed (type 1) or cardioinhibitory response (Type 2A and 2B) Negative impact on work and social life Non-respondent to pharmacological therapy (Fludrocortisone 0.1mg / 24 hours for 3 months) and non-pharmacological (exercise, hydration and consumption of more than 3 months) is due to a cardiologist who has performed a strict stricture over time At least 2 episodes of syncope in the last year  Complete atrioventricular block Second degree ventricular atrial block Bradycardia syndrome tachycardia Disease of the sinus node Arrhythmia (bradycardia or tachycardia that generate syncope and / or low cardiac output) Syncope due to hypersensitivity of the carotid sinus Syncope with Tilt Test that demonstrates depressant vasopressor response (type 3) Refusal of the patient, his relatives or the attending physician to participate in the study
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 45.0-75.0,  Parkinson's Disease With Cognitive Impairment All patients with Parkinson's Disease who were diagnosed according to UK bank for PD, Aged 45-75 years, with for cognitive impairment (Mini-Mental Status Examination< 24), and consent obtained from the patient or his caregiver  History of repeated head injury History of repeated cerebrovascular strokes History of defined encephalitis Oculogyric crisis, supranuclear gaze palsy Family history of more than one relative History of drug intake as antipsychotics or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure Moderate and Severe depression (Hamilton Depression Rating Scale score >16) severe dysautonomia Cerebellar signs Babinski sign
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson Disease Patients diagnosed with PD by UK Brain Bank Diagnostic and other standard criteria  Lack of capacity to consent to participate in the project
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 22.0-999.0,  Parkinson Disease Adult patients diagnosed with primary and secondary diagnosis of Parkinson's disease Patient 22 years old and older Patients admitted to inpatient units Patient who are verbally informed and agree to participate in the study  Patients less than or equal to 21 years of age Patients who refuse to wear the PD wrist band Patients who verbally refuse enrollment in the PD registry